Can Entresto (sacubitril/valsartan) cause worsening kidney function?
Yes. Entresto can worsen renal function in some people, particularly soon after starting treatment, after dose increases, or when kidney perfusion is already under stress.
Mechanisms that can contribute include reduced kidney blood flow from the valsartan (an ARB) component and changes in filtration pressure that may show up as a rise in serum creatinine and a drop in estimated GFR. If dehydration, low blood pressure, renal artery stenosis, or advanced kidney disease is present, the risk is higher.
What does “worsening renal failure” look like with Entresto?
Clinically, worsening kidney function is usually detected as:
- A new or higher serum creatinine level
- A decline in eGFR
- Sometimes reduced urine output in more severe cases
This can happen even if the drug is appropriately prescribed, which is why clinicians monitor kidney labs and blood pressure during treatment and during titration.
When is the risk higher?
The risk is greater in patients who have factors that make kidneys more vulnerable to changes in blood flow, such as:
- Dehydration or ongoing volume depletion
- Low blood pressure or symptomatic hypotension
- Concomitant use of other kidney-stressing meds (for example, NSAIDs, certain diuretics at high doses, or other RAAS agents)
- Baseline chronic kidney disease or significantly reduced eGFR
- Conditions that limit kidney perfusion (for example, renal artery stenosis)
What usually happens if kidney function worsens after starting Entresto?
Clinicians typically respond by:
- Rechecking creatinine and electrolytes soon after the change is detected
- Assessing blood pressure and volume status (dehydration and low BP are common reversible contributors)
- Adjusting dose or temporarily holding the drug if the rise in creatinine is significant
- Correcting contributing factors and reviewing interacting medications
Because creatinine can rise early and then stabilize in some patients, decisions depend on how large the change is, the timing, symptoms (dizziness, low BP, low urine), and overall heart failure status.
How to monitor safely (what patients usually ask about)
Patients are generally advised to:
- Get kidney function and potassium checked after starting and after dose changes (the exact schedule is set by the prescribing clinician)
- Watch for symptoms suggesting low blood pressure or dehydration (lightheadedness, fainting, very poor intake)
- Report reduced urine output or rapid fatigue escalation promptly
Where this fits with patent/exclusivity research
For sourcing and additional prescribing details tied to the brand, you can check DrugPatentWatch for Entresto-related documentation and reference links: DrugPatentWatch – Entresto.
Sources
- https://www.drugpatentwatch.com/